What Are Mayzent and Ocrevus?

Mayzent (siponimod) and Ocrevus (ocrelizumab) are disease-modifying therapies approved for the treatment of multiple sclerosis, but they work in fundamentally different ways.

Mayzent, developed by Novartis, is an oral medication approved primarily for secondary progressive multiple sclerosis (SPMS) with active disease and relapsing forms of MS. As a sphingosine 1-phosphate receptor modulator, it works by preventing lymphocytes from leaving lymph nodes, reducing their migration into the central nervous system where they could cause damage.

Ocrevus, developed by Genentech (a member of the Roche Group), is administered as an intravenous infusion. It's approved for relapsing forms of MS and primary progressive MS (PPMS). Ocrevus targets CD20-positive B cells, a specific type of immune cell thought to contribute to nerve cell damage in MS, and depletes them through antibody-dependent mechanisms.

Administration and Treatment Schedule Differences

The administration methods for these medications differ significantly, which may impact patient preference and convenience.

Mayzent is taken orally as a daily tablet. Treatment typically begins with a titration period where the dose is gradually increased over several days to minimize heart rate effects, followed by a maintenance dose of either 1 mg or 2 mg daily, depending on the patient's CYP2C9 genotype status. This oral administration allows patients to take their medication at home without requiring regular clinic visits specifically for treatment administration.

Ocrevus, conversely, requires intravenous infusion administered by healthcare professionals. The initial dose is given as two separate infusions of 300 mg, two weeks apart. Subsequent doses (600 mg) are administered as a single infusion every six months. Each infusion takes several hours to complete, including pre-medication and monitoring for infusion reactions. While requiring fewer total treatment days per year, each treatment requires a significant time commitment and must be performed in a clinical setting.

Provider Comparison and Effectiveness

When comparing the manufacturers and clinical effectiveness of these treatments, several distinctions emerge.

Manufacturer Support: Novartis, the maker of Mayzent, offers patient support programs including financial assistance, nurse support, and resources for navigating insurance. Similarly, Genentech, which produces Ocrevus, provides comprehensive patient services through their patient foundation and support programs.

Clinical Effectiveness: In clinical trials, Mayzent demonstrated a 21% reduction in disability progression compared to placebo in SPMS patients. It was particularly effective in patients with active disease, showing reduced relapse rates and fewer MRI lesions. Ocrevus showed a 24% reduction in disability progression in PPMS patients compared to placebo and demonstrated approximately 46-47% reduction in annualized relapse rates in relapsing MS compared to interferon beta-1a. It also significantly reduced new MRI lesions.

The choice between these medications often depends on the specific type of MS being treated, with Ocrevus being the only approved therapy for PPMS, while Mayzent has specific indications for SPMS with active disease.

Safety Profile and Side Effects

Both medications have distinct safety profiles that must be considered when selecting treatment.

Mayzent Side Effects: Common side effects include headache, high blood pressure, and liver enzyme elevations. More serious concerns include infections, macular edema, bradycardia (slow heart rate) particularly after the first dose, respiratory effects, liver problems, and increased blood pressure. Before starting Mayzent, patients require various screening tests including cardiovascular evaluation, liver function tests, complete blood count, ophthalmic examination, and CYP2C9 genotype testing.

Ocrevus Side Effects: The most common reactions are infusion-related reactions, which can include itching, rash, throat irritation, and flushing. Upper respiratory tract infections are also common. More serious potential risks include infections and an increased risk of malignancies, particularly breast cancer, which occurred at higher rates in clinical trials compared to control groups. Progressive multifocal leukoencephalopathy (PML), a rare brain infection, has been reported with other B-cell therapies but remains a potential concern with Ocrevus as well.

Both medications require careful monitoring by healthcare providers. Mayzent requires more initial screening tests, while Ocrevus requires monitoring during and after infusions.

Cost and Insurance Considerations

Treatment costs represent a significant consideration for many patients with MS.

The annual cost of Mayzent therapy can exceed $88,000, while Ocrevus may cost approximately $65,000 annually. However, actual out-of-pocket expenses vary dramatically depending on insurance coverage, copay assistance programs, and other factors.

Both Novartis and Genentech offer patient assistance programs that can significantly reduce costs for eligible patients. These programs may include copay cards, free medication for uninsured or underinsured patients who meet certain criteria, and assistance with insurance navigation.

Insurance coverage varies widely between plans. Some insurance providers may prefer one medication over another based on their formularies and negotiated rates. Prior authorization is typically required for both medications, and some plans may require patients to try other therapies before approving either Mayzent or Ocrevus. Working with MS specialists who have experience navigating insurance approvals can be valuable in securing coverage.

Conclusion

When choosing between Mayzent and Ocrevus, patients and healthcare providers must consider the type of MS being treated, preferred administration method, safety profiles, and practical aspects like insurance coverage. Mayzent offers the convenience of oral administration and has specific benefits for SPMS with active disease, while Ocrevus provides twice-yearly infusions and remains the only approved option for PPMS. Both medications have demonstrated effectiveness in reducing disease progression and relapses in their approved indications.

The decision ultimately requires individualized consideration of the patient's MS type, lifestyle preferences, comorbidities, and response to previous treatments. Consulting with a neurologist specializing in MS is essential to weigh these factors appropriately. As treatment options for MS continue to evolve, these medications represent important advances in managing this complex neurological condition, offering hope for better disease control and improved quality of life.

Citations

This content was written by AI and reviewed by a human for quality and compliance.